Seres Therapeutics' ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association

Author's Avatar
Oct 19, 2022

Seres+Therapeutics%2C+Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the %3Ci%3EJournal+of+the+American+Medical+Association%3C%2Fi%3E (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.